title: Breast cancer: Zoledronic acid--more than just a bone drug.
abstract: Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.
authors.affiliation: University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Center Avenue, Pittsburgh, PA 15232, USA.
authors.forename: Aju
authors.initials: A
authors.lastname: Mathew
authors.affiliation: University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Center Avenue, Pittsburgh, PA 15232, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Brufsky
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid